Beyond Barriers

A novel technology platform
for the delivery of therapeutics
across biological barriers

Gate2Brain

The solution

Gate2Brain
Technology

Gate2Brain (G2B) uses a novel technology platform for the delivery of therapeutics. Our platform is based on three families of peptide shuttles that improve the biopharmaceutical properties of cargoes such as small molecules, peptides, nanoparticles, proteins and antibodies in vitro and in vivo when conjugated to them.

The G2B technology platform is applicable to therapeutic areas in which biological barriers hinder the delivery and activity of drugs.

About us

Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological barriers such as the blood-brain barrier. We pursue our goals using a radically innovative peptide-based patented technology platform.

Pipeline and Therapeutic Proof of Concept

G2B-002, the first therapeutic proof of concept of our technology platform, is aimed mainly at the treatment of rare pediatric solid tumors.

Medicines beyond barriers

We go beyond physiological and disease barriers, as our portfolio of peptide shuttles cover barriers such as the blood-brain,
blood-retinal, skin and tumor barriers.
We go beyond economic barriers, such as the lack of investment for the development of pediatric drugs. We go beyond societal barriers to provide medicines for everyone, everywhere.

Clinical Focus

Therapeutic
Proof of Concept

Our G2B therapeutic-peptide shuttle conjugates carry the drug cargo candidates to the target site in which the disease arises. G2B-002, our flagship product and proof of concept of the technology, offers a new therapeutic approach with improved biopharmaceutical properties and potent activity against rare pediatric cancers.

Our objective is for G2B-002 to reach Phase 1 clinical trials and thus have a high social impact focused on the unmet medical needs of oncology, pediatric and rare diseases.

G2B-002 shows potent preclinical activity for rare pediatric cancer indications such as pediatric high-grade gliomas, DIPG, Ewing sarcoma, rhabdomyosarcoma and neuroblastoma.

Gate2Brain

News & Media

Welcome to our news section, which provides a selection of our coverage in the media, industry, latest developments, plus videos, and more.

VII SEQT Summer School “Medicinal Chemistry and Chemical Biology in Drug DiscoveryGate2Brain

Gate2Brain at the VII SEQT Summer School

Our CEO, Meritxell Teixidó, participated as a speaker to the VII SEQT Summer School “Medicinal Chemistry…
internship Eada

EADA Master students at Gate2Brain

As part of their International Master in Management and International Master in Pharmaceutical and Biotechnology…
Nadia Calviño, First Vice President of the Government and Minister of Economic Affairs visits Gate2BrainSJD

Nadia Calviño, First Vice President of the Government visits Gate2Brain

Nadia Calviño, First Vice President of the Government and Minister of Economic Affairs, and Maria Eugènia…
Thank you for inviting Gate2Brain last Friday to the conference "DIGITALIZING AND REINDUSTRIALIZING SPAIN WITH THE RECOVERY PLAN". The purpose of this conference, focused on the digital axis of the Recovery Plan, was to give visibility to some of the digitization projects that have already received funding from the Plan in different areas and that are already contributing to this transformation, as well as to present the evolution of the Digital Spain agenda.Asuntos Económicos y transformación digital

Gate2Brain at “Digitalizing and reindustrializing Spain with the recovery plan”

Gate2Brain last Friday at the conference "DIGITALIZING AND REINDUSTRIALIZING SPAIN WITH THE RECOVERY…
It’s Gate2Brain second anniversary!! 🎂 The creativity, work and dedication of Gate2Brain's team can only be matched with its desire to bring medicines beyond barriers.Gate2Brain

Gate2Brain second anniversary

It’s Gate2Brain second anniversary!! The creativity, work and dedication of Gate2Brain's team can…
Gate2Brain participated on June 29 at The Milner Therapeutics Institute (MTI) Pitch Day 🗣️at the University of Cambridge, the cradle of cancer research. The MTI Pitch Day is a great initiative designed to highlight companies like us to investors, to create connections between academic entrepreneurship and investment to promote therapeutic companies. A great event that pulls together on one side academic, preclinical and research and on the other industry in an effort to push forward collaborative drug development and increase the standard of patient care

Gate2Brain at MIT Pitch Day at University of Cambridge

Gate2Brain participated on June 29 at The Milner Therapeutics Institute (MTI) Pitch Day at the University…
medicines beyond barriersG2B

Medicines beyond barriers

At Gate2Brain, we have found the key to unlocking the gate to the brain . We have developed a unique…
EITHealth Catapult 2022eithealth

Gate2Brain semifinalist of EITHealth’s Catapult 2022

We’re proud to share that Gate2Brain is semifinalist of EITHealth's Catapult 2022.Thanks to…
Una tecnología para ayudar a tratar el cáncer infantilgate2brain

A technology to help treat pediatric cancer

Una tecnología para ayudar a tratar el cáncer infantilExpansión. Madrid. La tecnología de…

1
2
Gate2Brain
1

Making therapies a reality for patients by addressing unmet medical needs.

2

Improving patients’ quality of life using a technology that provides superior drug transport efficacy.

Go Beyond Barriers & Contact Us

This contact form is deactivated because you refused to accept Google reCaptcha service which is necessary to validate any messages sent by the form.

Barcelona Scientific Park
Baldiri Reixac, 4-8, Torre I
08028 Barcelona, Spain
info@gate2brain.com

Gate2Brain
Gate2Brain
Gate2Brain
Gate2Brain
Gate2Brain